1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. (December 2022) Authors: Bahl, Amit; Wilson, William; Ball, Jessica; Renninson, Emily; Dubey, Sidharth; Bravo, Alicia; Foulstone, Emily; Spensley, Saiqa; Bowen, Rebecca; Mansi, Janine; Waters, Simon; Riddle, Pippa; Wheatley, Duncan; Stephens, Peter; Bezecny, Pavel; Madhusudan, Srinivasan; Verrill, Mark; Braybrooke, Jerem... Journal: Breast Issue: Volume 66(2022) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Engendering Hope: A Person-Centred Reflection on Technology and Gender†. Issue 1 (2nd January 2016) Authors: Waters, Simon Journal: Contemporary music review Issue: Volume 35:Issue 1(2016) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Issue 3 (March 2020) Authors: Jones, Robert H; Casbard, Angela; Carucci, Margherita; Cox, Catrin; Butler, Rachel; Alchami, Fouad; Madden, Tracie-Ann; Bale, Catherine; Bezecny, Pavel; Joffe, Johnathan; Moon, Sarah; Twelves, Chris; Venkitaraman, Ramachandran; Waters, Simon; Foxley, Andrew; Howell, Sacha J Journal: Lancet oncology Issue: Volume 21:Issue 3(2020) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Issue 7 (July 2022) Authors: Howell, Sacha J; Casbard, Angela; Carucci, Margherita; Ingarfield, Kate; Butler, Rachel; Morgan, Sian; Meissner, Magdalena; Bale, Catherine; Bezecny, Pavel; Moon, Sarah; Twelves, Chris; Venkitaraman, Ramachandran; Waters, Simon; de Bruin, Elza C; Schiavon, Gaia; Foxley, Andrew; Jones, Robert H Journal: Lancet oncology Issue: Volume 23:Issue 7(2022) Page Start: 851 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. (August 2022) Authors: Wildiers, Hans; Meyskens, Thomas; Marréaud, Sandrine; Lago, Lissandra Dal; Vuylsteke, Peter; Curigliano, Giuseppe; Waters, Simon; Brouwers, Barbara; Meulemans, Bart; Sousa, Berta; Poncet, Coralie; Brain, Etienne Journal: Breast Issue: Volume 64(2022) Page Start: 100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Issue 3 (March 2018) Authors: Wildiers, Hans; Tryfonidis, Konstantinos; Dal Lago, Lissandra; Vuylsteke, Peter; Curigliano, Giuseppe; Waters, Simon; Brouwers, Barbara; Altintas, Sevilay; Touati, Nathan; Cardoso, Fatima; Brain, Etienne Journal: Lancet oncology Issue: Volume 19:Issue 3(2018) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The entanglements which make instruments musical: Rediscovering sociality. Issue 2 (15th March 2021) Authors: Waters, Simon Journal: Journal of new music research Issue: Volume 50:Issue 2(2021) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗